Seven new genes have been linked to melanoma, say researchers at the National Cancer Institute, providing potential targets for antitumor immunotherapy drugs. These genes are overexpressed in melanomas, but are hardly active in normal tissue, so targeting them should have minimal side effects. Two of the genes are specific to melanoma (CSPG4 and SOX10), while the remaining five are in a well-known family of cancer genes (CSAG2, IL13RA2, MAGEA3, MAGEC2, and PRAME). The researchers hope to engineer people's immune cells to recognize these targets and kill melanoma cells, a strategy that is currently being tested in clinical trials for other types of cancer. In addition, the researchers are extending their search for immunotherapy targets to pancreatic cancer.